Current Xanax Production Status
Xanax, the brand name for alprazolam, is still manufactured and available in the United States. The original brand-name product is produced by Pfizer, while multiple generic versions are made by other licensed manufacturers. The U.S. Food and Drug Administration (FDA) continues to approve alprazolam products, and the drug remains a Schedule IV controlled substance under the Controlled Substances Act. Pfizer and other generic manufacturers continue to supply pharmacies across the country, though supply chains and manufacturing standards are closely monitored by federal regulators FDA.
The production of Xanax is concentrated among a limited number of active pharmaceutical ingredient (API) suppliers and formulation facilities. The FDA maintains a public database of drug shortages and manufacturing inspections, and recent reports show ongoing compliance actions at some facilities that produce alprazolam. Despite these actions, the agency has not removed Xanax or its generics from the market, and the drug continues to be dispensed by licensed pharmacies nationwide.
Market Availability and Demand
Xanax remains one of the most prescribed benzodiazepines in the United States, with millions of prescriptions filled annually. The drug is widely available in tablet, extended-release, and oral concentrate forms, and generic alprazolam products are typically covered by most commercial insurance plans and Medicare Part D. According to industry data and pharmacy benefit manager reports, alprazolam consistently ranks among the top prescribed psychiatric medications in the country Forbes.
Retail pharmacies, including major chains and online pharmacy platforms, continue to stock Xanax and its generics. However, the drug is subject to strict prescribing regulations, including limits on quantity and mandatory use of prescription drug monitoring programs (PDMPs) in many states. The Drug Enforcement Administration (DEA) tracks alprazolam distribution closely, and pharmacies must comply with federal and state rules regarding storage, dispensing, and recordkeeping.
Regulatory and Legal Framework
The legal status of Xanax in the United States is governed by the Controlled Substances Act, which classifies alprazolam as a Schedule IV drug due to its potential for dependence and abuse. The DEA sets annual manufacturing quotas for alprazolam, and the FDA reviews applications for new generic approvals and brand-name extensions. Recent enforcement actions have focused on preventing diversion and illegal online sales, with the agency working alongside pharmacies and law enforcement to monitor supply chains DEA.
State-level regulations further shape how Xanax is prescribed and dispensed. Many states have implemented pill counts, mandatory PDMP checks, and limits on initial prescriptions for benzodiazepines. These rules aim to reduce misuse and diversion while ensuring that patients with legitimate medical needs can access the medication. The FDA also issues safety communications and labeling updates to inform prescribers and patients about risks, including dependence, withdrawal, and interactions with other central nervous system depressants FDA Drugs.